These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33902068)

  • 1. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
    Zhou S; Dong X; Chen C; Ma L; Wu Y; Zhou Y; Cui Y
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):203-210. PubMed ID: 33902068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
    N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
    Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
    Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
    Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
    Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
    Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
    Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
    Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
    Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Lee JW; Kulasekararaj AG
    Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
    [No Abstract]   [Full Text] [Related]  

  • 9. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
    Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
    Scheinberg P; Clé DV; Kim JS; Nur E; Yenerel MN; Barcellini W; Bonito D; Giai V; Hus M; Lee Y; Lekue CB; Panse J; Ueda Y; Buatois S; Gentile B; Kiialainen A; Patel H; Sreckovic S; Uguen M; Edwards J; Nagy Z; Kulasekararaj AG
    Am J Hematol; 2024 Sep; 99(9):1757-1767. PubMed ID: 38924124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
    Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
    Front Immunol; 2019; 10():1639. PubMed ID: 31379839
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
    Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
    Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
    Chonat S; Kulagin A; Maschan A; Bartels M; Buechner J; Punzalan R; Richards M; Ogawa M; Hicks E; Yu J; Baruchel A; Kulasekararaj AG
    Blood Adv; 2024 Jun; 8(11):2813-2824. PubMed ID: 38551806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab in pregnancy: a narrative overview.
    Sarno L; Tufano A; Maruotti GM; Martinelli P; Balletta MM; Russo D
    J Nephrol; 2019 Feb; 32(1):17-25. PubMed ID: 30159857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
    McQuillen DP; Ram S
    Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
    [No Abstract]   [Full Text] [Related]  

  • 16. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
    Ishiyama K; Nakao S; Usuki K; Yonemura Y; Ikezoe T; Uchiyama M; Mori Y; Fukuda T; Okada M; Fujiwara SI; Noji H; Rottinghaus S; Aguzzi R; Yokosawa J; Nishimura JI; Kanakura Y; Okamoto S
    Int J Hematol; 2020 Oct; 112(4):466-476. PubMed ID: 32869125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
    Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
    Lee SE; Lee JW
    Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
    Röth A; He G; Tong H; Lin Z; Wang X; Chai-Adisaksopha C; Lee JH; Brodsky A; Hantaweepant C; Dumagay TE; Demichelis-Gómez R; Rojnuckarin P; Sun J; Höglund M; Jang JH; Gaya A; Silva F; Obara N; Kelly RJ; Beveridge L; Buatois S; Chebon S; Gentile B; Lundberg P; Sreckovic S; Nishimura JI; Risitano A; Han B
    Am J Hematol; 2024 Sep; 99(9):1768-1777. PubMed ID: 38884175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.